Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed chronic lymphocytic leukemia OR small lymphocytic lymphoma * Stage III-IV OR * Stage I-II, if determined to have disease progression evidenced by 1 of the following characteristics: * Rapid doubling of peripheral lymphocyte count * Progressive lymphadenopathy * Progressive splenomegaly * B symptoms * Grade 2 or 3 fatigue * CD23+ disease * Progressive disease after at least 1 prior chemotherapy course PATIENT CHARACTERISTICS: Age * 18 and over Performance status * WHO 0-2 Life expectancy * At least 6 months Hematopoietic * Platelet count at least 50,000/mm\^3 Hepatic * Bilirubin no greater than 2.0 mg/dL * AST/ALT no greater than 1.5 times upper limit of normal (ULN) Renal * Creatinine no greater than 1.5 times ULN Cardiovascular * No New York Heart Association class III or IV cardiac disease * No myocardial infarction within the past 6 months * No unstable arrhythmia * No evidence of ischemia on EKG within the past 14 days Pulmonary * FEV\_1 at least 60% of predicted * DLCO at least 55% of predicted Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study treatment * HIV negative * No secondary malignancy requiring active treatment (except hormonal therapy) * No serious nonmalignant disease that would preclude study participation * No active uncontrolled bacterial, viral, or fungal infection * No clinically active autoimmune disease PRIOR CONCURRENT THERAPY: Biologic therapy * More than 4 weeks since prior anticancer biologic therapy * More than 4 weeks since prior anticancer radioimmunotherapy * No prior exposure to IDEC-152 or anti-CD23 antibodies Chemotherapy * See Disease Characteristics * More than 4 weeks since prior anticancer chemotherapy Endocrine therapy * Concurrent hormonal therapy allowed for second malignancy Radiotherapy * More than 4 weeks since prior anticancer radiotherapy Surgery * More than 4 weeks since prior major surgery (except for diagnostic surgery) Other * More than 4 weeks since prior anticancer investigational therapy * No other concurrent anticancer therapy